CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma

High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or primary refractory (rel/ref) chemorefractory diffuse large B-cell lymphoma. Only 50% of patients are cured with this approach. We investigated safety and efficacy of CD19-specific chime...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Sauter, Craig S., Senechal, Brigitte, Rivière, Isabelle, Ni, Ai, Bernal, Yvette, Wang, Xiuyan, Purdon, Terence, Hall, Malloury, Singh, Ashvin N., Szenes, Victoria Z., Yoo, Sarah, Dogan, Ahmet, Wang, Yongzeng, Moskowitz, Craig H., Giralt, Sergio, Matasar, Matthew J., Perales, Miguel-Angel, Curran, Kevin J., Park, Jae, Sadelain, Michel, Brentjens, Renier J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Immunobiology and Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6695562/
https://ncbi.nlm.nih.gov/pubmed/31262783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2018883421
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados